Inclusion Criteria:

- Absolute neutrophil count >= 1,500/mm3

- No psychiatric illness or social situation that would preclude study compliance

- Chemotherapy administered solely as a radiosensitizer or as adjuvant therapy and
investigational or targeted therapies (i.e., inhibitors of the epidermal growth
factor receptor) will not count toward the maximum of 2 prior regimens allowed

- Histologically or cytologically confirmed adenocarcinoma of the intrahepatic or
extrahepatic bile duct or gallbladder:

- Locally advanced or metastatic disease

- At least 1 unidimensionally measurable lesion >=20 mm by conventional techniques OR
>= 10 mm by spiral CT scan

- Not amenable to curative surgical resection

- No known brain metastases

- Performance status:

- ECOG 0-2

- Life expectancy:

- More than 12 weeks

- Platelet count >= 100,000/mm3

- WBC >= 3,000/mm3

- AST and ALT ≤ 2.5 times upper limit of normal (ULN) [Note: Biliary shunting or
stenting allowed to achieve the required bilirubin and transaminase levels]

- Bilirubin ≤ 1.5 times ULN [Note: Biliary shunting or stenting allowed to achieve the
required bilirubin and transaminase levels]

- Creatinine within ULN OR Creatinine clearance >= 60 mL/min

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No symptomatic cardiac arrhythmia within the past 4 weeks

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No underlying neuropathy >= grade 2

- No history of allergic reaction to boron, mannitol, or bortezomib

- No active or ongoing infection

- No concurrent uncontrolled illness

- No medical or psychiatric condition that would preclude study participation

- No prophylactic granulocyte or platelet growth factors (filgrastim [G-CSF] or
sargramostim [GM-CSF])

- Prior chemotherapy as a radiosensitizer (e.g., fluorouracil or gemcitabine) with
radiotherapy is allowed as adjuvant therapy after resection for locally advanced
disease provided there is evidence of disease progression

- No more than 2 prior chemotherapy regimens for locally advanced or metastatic disease

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent anticancer agents or therapies

- No other concurrent investigational agents